Clinical Trial

Experimental Treatment for Focal Epilepsy

Study Description

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - XEN1101

Oral dose

Additional Information

Official Study Title

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Epilepsy

Clinical Trial ID

NCT03796962

ParticipAid ID

av2DVa